This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...

Aligos has initiated dosing in the Phase II B-SUPREME trial of its ALG-000184 in people with chronic hepatitis B virus (HBV) ...

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.

The Phase II STARLIGHT study (NCT05417126) found that a single intravitreal injection of gene-agnostic MCO-010 in six ...

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome ...

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.

The device for endotoxic septic shock was first approved in Europe more than 20 years ago, in 1994, by Toray Industries.